Free public records show Shenzhen Salubris Pharmaceuticals Co., Ltd. in 5 of the markets we cover. It is not a key player in our research.
[1] ClinicalTrials.gov, Studies led by Shenzhen Salubris Pharmaceuticals Co., Ltd. or a part of it that are recruiting, about to start or running. Retrieved 13 Nov 2026.
From public registers, not from Acuitas research, with a citation under every number. Each card opens the full list at its source.
Source: Wikidata, Company record Q20716869. Retrieved 13 Nov 2026.
20 active studies led by Shenzhen Salubris Pharmaceuticals Co., Ltd., of 42 in all
Source: ClinicalTrials.gov, Studies with Shenzhen Salubris Pharmaceuticals Co., Ltd. (or a part of it) as lead sponsor; active = recruiting, about to start or running. Retrieved 13 Nov 2026.
Studies Shenzhen Salubris Pharmaceuticals Co., Ltd. leads, by the year they started and their phase
Source: ClinicalTrials.gov, Studies with Shenzhen Salubris Pharmaceuticals Co., Ltd. or a part of it as lead sponsor, by start year (since 2015) and phase. Retrieved 13 Nov 2026.
Markets we cover where free public records show Shenzhen Salubris Pharmaceuticals Co., Ltd.: trials they lead, US approvals or WHO prequalification. Each opens the market's report, with the record counts and their sources.
The topics of the markets Shenzhen Salubris Pharmaceuticals Co., Ltd. is in.
Stories on the topics Shenzhen Salubris Pharmaceuticals Co., Ltd. works in.
Omega-3 supplements are hugely popular. Big trials give mixed answers on whether they protect the heart.
Read
Nearly 15% of US Medicare beneficiaries, 8.2 million people, had a wound or wound infection in one year…
Read
Cardiovascular disease is the world's leading cause of death, and stroke caused 11.9 million new cases in…
ReadSearch all reports for Shenzhen Salubris Pharmaceuticals Co., Ltd. All companies